01:23 , Mar 31, 2018 |  BioCentury  |  Strategy

Refashioning Takeda

Takeda Pharmaceutical Co. Ltd.’s potential acquisition of Shire plc appears to be timed to take advantage of the chance to acquire products and a global footprint on the cheap. The combination would create a global biopharma...
19:58 , Aug 4, 2017 |  BC Week In Review  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
23:20 , Aug 3, 2017 |  BC Extra  |  Company News

Shire evaluating neurology pipeline

In its 2Q17 earnings report, Shire plc (LSE:SHP; NASDAQ:SHPG) said it will evaluate options for its neurology franchise, with the potential of spinning out the company’s core ADHD business into an independent public company. The...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other molecule...
19:21 , Jul 13, 2017 |  BC Innovations  |  Translation in Brief

Mind over matter

In the latest link between the GI tract and the CNS, a team from the Max Delbrück Center for Molecular Medicine has identified the synaptic organizers CADM1 and CADM2 as targets in the gut-brain axis...
18:05 , Jul 10, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Obesity Human sample and mouse studies suggest inhibiting CADM1 in the brain could help treat obesity. In brain tissue samples from non-obese surgery patients and postmortem subjects, levels of CADM1 in the hypothalamus were associated...
00:56 , Mar 29, 2017 |  BC Week In Review  |  Clinical News

CM-24: Ph I terminated

Merck terminated an open-label, dose-escalation, U.S. and Israeli Phase I trial evaluating CM-24 in combination with Keytruda pembrolizumab in 27 patients. The company said CM-24 showed no signs of efficacy in the trial and that...
19:44 , Mar 23, 2017 |  BC Extra  |  Clinical News

Merck ends development of cCAM compound

Merck & Co. Inc. (NYSE:MRK) terminated development of oncology candidate CM-24, spokesperson Pamela Eisele told BioCentury. Eisele said the mAb showed no signs of efficacy in a dose-ranging Phase I study in combination with Keytruda...
23:06 , Nov 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Going against the gut

While patients might have a long wait for an HIV vaccine, several groups are working on the next best thing: strategies that boost patient immune systems to control the infection without the need for daily...
07:00 , Aug 4, 2016 |  BC Innovations  |  Product R&D

Antibiotic wisdom

While one of the biggest problems in infectious diseases is the overuse of antibiotics, few point-of-care tools are available to help physicians decide when and what to prescribe. Focusing on host genes rather than microbial...